CLDI · XBRL financial data

Calidi Biotherapeutics financial statements, every fiscal year

The same tables from 6 filings, lined up. Matched by XBRL tag: renamed lines keep their history.

How these numbers work

Every number comes from the company's XBRL financial data filed with the SEC, and each one links to its filing.
Lines are matched by XBRL tag, so a line renamed between filings keeps its history.
* marks a quarter worked out from the filing totals: the 10-K year minus the first three quarters, or a year-to-date total minus the earlier one. Fourth-quarter earnings per share is fourth-quarter net income over the fourth-quarter weighted shares.
0 means a filing states zero; a dash (—) means no filing states that number.
“year only” means the 10-K gives the full year but not the quarters needed to work out the fourth. A worked-out quarter of revenue, cost of revenue or operating cash flow more than twice the company's largest quarter of the two years before is shown this way too.
Gross profit is shown as the company reports it; a worked-out quarter must equal revenue less cost of revenue for that quarter, or it is a dash.
Operating income can be above gross profit when the company books other operating income between the two, shown on its own line.
Shares outstanding come from each filing's cover page, as of the date printed there.
Quarters are fiscal: Q2 FY27 is the second quarter of the company's fiscal 2027.

Income statement

Fiscal years (CLDI's year ends in late December)

In thousands of dollars	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Revenue from contracts with customers	—	45	—	—	—
Research and development	—	7,257	13,008	8,878	9,737
Selling, general and administrative	—	15,902	15,984	12,898	10,503
Total operating expenses	—	4,670	28,992	21,776	20,240
Operating income (loss)	—	(4,670)	(28,992)	(21,776)	(20,240)
Interest expense	—	200	1,100	700	100
Other income (expense)	—	(5)	(51)	9	103
Income tax expense (benefit)	—	347	16	14	15
Net income (loss)	—	3,530	(29,216)	(22,143)	(19,906)
Earnings per share, basic USD per share	—	2.99	1.73	(2.97)	(5.95)
Earnings per share, diluted USD per share	—	2.99	1.73	(2.97)	(5.95)
Weighted average shares, basic thousands of shares	—	8,505	16,887	8,005	4
Weighted average shares, diluted thousands of shares	—	8,505	16,887	8,005	4

Fiscal years (CLDI's year ends in late December)

In thousands of dollars	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Cash and cash equivalents	1,063	94	2,167	9,600	5,819
Accounts receivable	0	1	—	—	—
Prepaid and other current assets	—	414	2,354	636	656
Total current assets	1,484	402	4,303	10,227	6,256
Property and equipment, net	—	1,270	1,270	869	781
Right-of-use asset	—	199	4,073	2,934	1,682
Total assets	231,769	42,855	10,019	14,182	8,857
Accounts payable	64	51	—	—	—
Accrued liabilities	347	3,220	—	—	—
Current portion of long-term debt	—	5,425	807	3,221	90
Total current liabilities	411	4,536	10,232	9,496	3,935
Lease liability, non-current	—	305	3,037	1,845	277
Total liabilities	16,451	5,607	18,254	12,214	5,098
Accumulated deficit	(14,687)	(5,206)	(99,572)	(121,715)	(141,621)
Total stockholders' equity	(14,687)	(5,205)	(8,235)	1,534	3,759
Total liabilities and equity	231,769	42,855	10,019	14,182	8,857
Common shares outstanding (cover page) thousands of shares	23,000	4,128	35,538	28,468	10,896

Fiscal years (CLDI's year ends in late December)

In thousands of dollars	FY 2021Dec 31, 2021	FY 2022Dec 31, 2022	FY 2023Dec 31, 2023	FY 2024Dec 31, 2024	FY 2025Dec 31, 2025
Net income (loss)	—	3,530	(29,216)	(22,143)	(19,906)
Stock-based compensation	—	4,522	4,809	2,957	2,108
Net cash from operating activities	—	98	(26,983)	(19,694)	(21,293)
Net cash from investing activities	—	187,686	(478)	(16)	(170)
Net cash from financing activities	—	(188,753)	29,044	27,365	17,459
Net change in cash	—	(969)	1,577	7,642	(3,990)

SIC 2836 and related industry codes, similar size. Each row is the latest quarter reported.

How peers are chosen

SIC 2836 and related industry codes with public float (or, where float is missing, quarterly revenue) between 0.2x and 5x the company's.
Each row is the latest quarter the company has reported, named in the Quarter column; when that filing is a 10-K, it is the fourth quarter, never the full year.
Runway shows only for companies burning cash with under $10B of public float.
* marks a quarter worked out from the filing totals: for a 10-K, the year less the first three quarters; for a 10-Q, the year-to-date total less the earlier one.
A cell reading “not reported” means the filings give no figure for that quarter alone.

Company	Cash ($K)	Revenue, quarter ($K)	Operating cash flow, quarter ($K)	Shares outstanding	Runway	Quarter
Calidi Biotherapeutics	4,290	not reported	(4,353)*	2.6M	1.0 quarters	Q2 FY26 10-QJun 30, 2026
Processa Pharmaceuticals	196	not reported	(1,996)*	2.8M	0.1 quarters	Q2 FY26 10-QJun 30, 2026
Talphera	742	not reported	(3,924)*	51.9M	4.4 quarters	Q2 FY26 10-QJun 30, 2026
Orgenesis	78	301*	(2,098)*	9.8M	0.0 quarters	Q4 FY24 10-KDec 31, 2024
Biovie	8,977	not reported	(4,122)*	7.5M	2.2 quarters	Q4 FY26 10-KJun 30, 2026
VivoSim Labs	1,670	18	(3,213)	14.9M	0.5 quarters	Q1 FY27 10-QJun 30, 2026
Genprex	15,154	not reported	(5,139)*	819,709	2.9 quarters	Q2 FY26 10-QJun 30, 2026
GT Biopharma	4,960	not reported	(4,260)*	45.1M	1.2 quarters	Q2 FY26 10-QJun 30, 2026
Intensity Therapeutics	9,529	not reported	(2,340)*	3.3M	4.1 quarters	Q2 FY26 10-QJun 30, 2026

Not investment advice. Not affiliated with the U.S. SEC.